Tenofovir Alafenamide
Composition:
Each
film coated tablet contains Tenofovir Alafenamide 25mg as Tenofovir Alafenamide
Fumarate INN.
Indications:
It is indicated for the treatment of chronic hepatitis B virus
infection in adults with compensated liver disease.
Dosage and Administration:
The recommended dosage is 25 mg (one tablet) taken orally once daily
with food. Or, as directed by the registered physician.
No
dosage adjustment of T-Fovir A is required in patients with mild, moderate, or
severe renal impairment. It is not recommended in patients with end stage renal
disease (estimated creatinine clearance below 15 ml/ min). No dosage adjustment
is required in patients with mild hepatic impairment (Child-Pugh A). It is not
recommended in patients with decompensated (Child-Pugh B or C) hepatic
impairment.
Use in Pregnancy and Lactation:
There
are no human data on the use of Tenofovir Alafenamide in pregnant women to
inform a drug-associated risk of adverse fetal developmental outcome. It is not
known whether Tenofovir Alafenamide and its metabolites are present in human
breast milk, affect human milk production, or have effects on the breastfed
infant.
Packing:
Each box contains 10’s tablets in blister pack.
